FLGT Stock Overview
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
Fulgent Genetics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$34.76 |
52 Week High | US$73.47 |
52 Week Low | US$28.53 |
Beta | 1.58 |
1 Month Change | 16.72% |
3 Month Change | -12.29% |
1 Year Change | -44.51% |
3 Year Change | 159.79% |
5 Year Change | 674.16% |
Change since IPO | 278.65% |
Recent News & Updates
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28Recent updates
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
Nov 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Oct 27We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
Sep 19Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
Jul 21Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Jun 04These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet
Jan 25I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease
Dec 14These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
Oct 16At US$85.24, Is Fulgent Genetics, Inc. (NASDAQ:FLGT) Worth Looking At Closely?
Sep 25If You Like EPS Growth Then Check Out Fulgent Genetics (NASDAQ:FLGT) Before It's Too Late
Sep 07Is Fulgent Genetics (NASDAQ:FLGT) A Risky Investment?
Jul 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Jun 04We Take A Look At Whether Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO May Be Underpaid
May 14Shareholder Returns
FLGT | US Healthcare | US Market | |
---|---|---|---|
7D | 6.5% | 0.2% | 2.8% |
1Y | -44.5% | -0.2% | -9.2% |
Return vs Industry: FLGT underperformed the US Healthcare industry which returned -0.2% over the past year.
Return vs Market: FLGT underperformed the US Market which returned -9.2% over the past year.
Price Volatility
FLGT volatility | |
---|---|
FLGT Average Weekly Movement | 7.1% |
Healthcare Industry Average Movement | 7.6% |
Market Average Movement | 6.9% |
10% most volatile stocks in US Market | 17.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: FLGT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: FLGT's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 645 | Ming Hsieh | https://www.fulgentgenetics.com |
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2.
Fulgent Genetics, Inc. Fundamentals Summary
FLGT fundamental statistics | |
---|---|
Market Cap | US$1.05b |
Earnings (TTM) | US$271.57m |
Revenue (TTM) | US$802.94m |
3.9x
P/E Ratio1.3x
P/S RatioIs FLGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FLGT income statement (TTM) | |
---|---|
Revenue | US$802.94m |
Cost of Revenue | US$259.48m |
Gross Profit | US$543.45m |
Other Expenses | US$271.88m |
Earnings | US$271.57m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 8.99 |
Gross Margin | 67.68% |
Net Profit Margin | 33.82% |
Debt/Equity Ratio | 1.6% |
How did FLGT perform over the long term?
See historical performance and comparison